Volatile applications against pathogens
US-9585396-B2 · Mar 7, 2017 · US
US10070649B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10070649-B2 |
| Application number | US-201715445247-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 28, 2017 |
| Priority date | Jan 30, 2013 |
| Publication date | Sep 11, 2018 |
| Grant date | Sep 11, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This invention is related to the use of a volatile antimicrobial compound against pathogens affecting humans comprising contacting infected areas with an atmosphere containing an effective amount of a volatile antimicrobial compound in gaseous form. The volatile antimicrobial compounds provided include certain oxaborole compounds, for example benzoxaboroles. Delivery systems are provided to take advantage of the volatile nature of these antimicrobial compounds. The method and use disclosed can be combined with other volatile compounds.
Opening claim text (preview).
We claim: 1. A method of using a volatile antimicrobial compound against an infection caused by fungal pathogens, comprising: contacting areas infected by the fungal pathogens with an atmosphere containing an effective amount of the volatile antimicrobial compound in gaseous form, the volatile antimicrobial compound having a structure of: and pharmaceutically or agriculturally acceptable salts thereof, wherein the infection is a vaginal yeast infection. 2. The method of claim 1 , wherein the fungal pathogens are selected from the group consisting of Candida albicans, C. tropicalis, C. glabrata, C. krusei, C. parapsilosis, C. dubliniensis, C. lusitaniae , or combinations thereof. 3. The method of claim 1 , wherein the fungal pathogens are Candida albicans. 4. The method of claim 1 , wherein the fungal pathogens are Candida krusei. 5. The method of claim 1 , further comprising coating a material for releasing the volatile antimicrobial compound in a gaseous form or absorbing the volatile antimicrobial compound into the material. 6. The method of claim 5 , wherein the material is an absorbent material or a fabric. 7. The method of claim 6 , wherein the absorbent material is selected from the group consisting of a panty liner pad or underwear. 8. The method of claim 6 , wherein the absorbent material is made of a component selected from the group consisting of cellulose, glass, polymer, nylon, and plastic fibers. 9. The method of claim 1 , wherein the volatile antimicrobial compound has the structure 10. The method of claim 1 , wherein the volatile antimicrobial compound has the structure 11. A method of using a volatile antimicrobial compound against an infection caused by fungal pathogens, comprising: (a) mixing the volatile antimicrobial compound with an organic solvent to form an antimicrobial solution; (b) applying the antimicrobial solution to a substrate or a device; (c) placing the substrate or the device in close proximity to an infected area by the fungal pathogens so that the gaseous form of the volatile antimicrobial compound releases near the infected area; and (d) contacting the infected area with an atmosphere containing an effective amount of the volatile antimicrobial compound in gaseous form at a temperature between 1° C. and 50° C.; wherein the volatile antimicrobial compound has a structure of: and pharmaceutically or agriculturally acceptable salts thereof, wherein the infection is a vaginal yeast infection. 12. The method of claim 11 , wherein the fungal pathogens are selected from the group consisting of Candida albicans, C. tropicalis, C. glabrata, C. krusei, C. parapsilosis, C. dubliniensis, C. lusitaniae , or combinations thereof. 13. The method of claim 11 , wherein the organic solvent comprises acetone or ethanol. 14. The method of claim 11 , wherein the fungal pathogens are Candida albicans. 15. The method of claim 11 , wherein the fungal pathogens are Candida krusei. 16. The method of claim 11 , wherein step (b) comprises coating a surface of the substrate or the device with the volatile antimicrobial compound or absorbing the volatile antimicrobial compound into the substrate or the device. 17. The method of claim 16 , wherein the substrate or the device is an absorbent material. 18. The method of claim 17 , wherein the absorbent material is selected from the group consisting of a panty liner pad or underwear. 19. The method of claim 11 , wherein the volatile antimicrobial compound has the structure 20. The method of claim 11 , wherein the volatile antimicrobial compound has the structure
containing boron · CPC title
in a controlled atmosphere comprising other gases in addition to CO2, N2, O2 or H2O · CPC title
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)} · CPC title
Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.